Synthesis and antitumor activity of novel podophyllotoxin derivatives against multidrug-resistant cancer cells

Journal of Asian Natural Products Research

Volumn 13, Issue 5, 2011, Pages 417-424

  Guo, Yong En ^a   Chen, Hong ^b,c   Zuo, Song ^b,c   Liu, Dai Lin ^b   Lu, Yan Ling ^b,c   Lv, Jing Jing ^b   Wen, Shao Peng ^a   Zhang, Tong Cun ^a  

^a TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

antitumor; cytotoxicity; indole; podophyllotoxin; prepare

Indexed keywords

4BETA 2 (N BENZOYL 4'' CARBOMETHOXYINDOL 3'' YL)GLYOXYLAMIDO 4 DEOXYPODOPHYLLOTOXIN; 4BETA 2 [N (2''' FLUOROBENZYL) 4'' CARBOMETHOXYINDOL 3'' YL]GLYOXYLAMIDO 4 DEOXYPODOPHYLLOTOXIN; PODOPHYLLOTOXIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN K 562; CELL STRAIN KB; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MULTIDRUG RESISTANCE; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, MULTIPLE; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; K562 CELLS; KB CELLS; MOLECULAR STRUCTURE; PODOPHYLLOTOXIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79957852100     PISSN: 10286020     EISSN: 14772213     Source Type: Journal    
DOI: 10.1080/10286020.2011.568941     Document Type: Article

References (22)

1. S.B. Kaye, Curr. Opin. Oncol 10, S15 (1998).
2. C. Ferlini, G. Raspaglio, S. Mozzeti, L. Cicchillitti, F. Fillippetti, D. Gallo, C. Fattorusso, G. Campiani, and G. Scambia, Cancer Res 65, 2397 (2005).
3. I. Wessel, P.B. Jensen, J. Falck, S.E.L. Mirski, S.P.C. Cole, and M. Sehested, Cancer Res 57, 4451 (1997).
4. K.H. Lee, Y. Iwakura, M. Haruna, S.A. Beers, and L.S. Thurston, J. Nat. Prod 52, 606 (1989).
5. X.M. Zhou, Z.W. Wang, J.Y. Zhang, H.X. Chen, and K.H. Lee, J. Med. Chem 34, 3346 (1991).
6. M. Gordaliza, M.A. Castro, and A.S. Feliciano, Curr. Pharmaceut. Res 6, 1811 (2000).
7. D.S.V. Vilet, Y. Tachibana, K.F. Bestow, E.S. Huang, and K.H. Lee, J. Med. Chem 44, 1422 (2001).
8. L. Schacter, Semin. Oncol 23, 1 (1996).
9. O. Pagani, M. Zucchetti, C. Sessa, J.D. Jong, M. D'Incalci, M.D. Fusco, A. Kaeser-Fröhlich, A. Hanauske, and F. Cavalli, Cancer Chemother. Pharmacol 38, 541 (1996).
10. K.R. Handel, Eur. J. Cancer 34, 1514 (1998).
11. A.K. Mukherjee, S. Basu, N. Sarkar, and A.C. Ghosh, Curr. Med. Chem 8, 1467 (2001).
12. K.H. Lee, S.A. Beers, M. Mori, Z.Q. Wang, Y.H. Kuo, L. Li, S.Y. Liu, J.Y. Chang, F.S. Han, and Y.C. Cheng, J. Med. Chem 33, 1364 (1990).
13. Z.Q. Wang, Y.H. Kuo, D. Schnur, J.P. Bowen, S.Y. Liu, F.S. Han, and K.H. Lee, J. Med. Chem 33, 2660 (1990).
14. Z. Xiao, Y. Li, and J. Feng, J. Med. Chem 45, 2294 (2002).
15. A. Kiselyov, K.V. Balakin, S.E. Tkachenko, N. Savchuk, and A.V. Ivachtchenko, Anti-Cancer Agents Med. Chem 7, 189 (2007).
16. G. Becher, B. Bickel, P. Emig, and S. Seeber, Cancer Res 61, 392 (2001).
17. P.F. Yu, H. Chen, J. Wang, C.X. He, B. Cao, M. Li, N. Yang, Z.Y. Lei, and M.S. Cheng, Chem. Pharm. Bull 56, 831 (2008).
18. G.C. Condie, M.F. Channon, A.J. Ivory, N. Kumar, and D.S. Black, Tetrahedron 61, 4989 (2005).
19. P.Z. Yu, L.P. Wang, and Z.N. Chen, J. Nat. Prod 54, 1422 (1991).
20. S. Kirchberg, R. Fröhlich, and A. Studer, Angew. Chem. Int. Ed 48, 4235 (2009).
21. C.J. Cao, Y.Y. Chen, Y.G. Wang, and Y.Z. Chen, Chin. Chem. Lett 10, 1003 (1999).
22. H. Chen, W.C. Li, and B. Cao, Eur. J. Pharmacol 627, 69 (2010).